West Tower Group’s United Therapeutics UTHR Stock Holding History

West Tower Group’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-31	Closed	-$6.82K	–	487
2023 Q4	$6.82K	Buy	+31	New	+$7.14K	0.01%	395

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

West Tower Group's UTHR Position: Q1 2024 in Review

West Tower Group sold out of United Therapeutics (UTHR) in Q1 2024, closing a stake of 31 shares — an estimated $6.82K sold.

West Tower Group first reported a position in UTHR in Q4 2023 and held it in 1 quarter. The position peaked at $6.82K in Q4 2023. 525 funds tracked by Wall St. Rank hold UTHR as of Q1 2024.

West Tower Group reported no remaining United Therapeutics position as of Q1 2024 after selling out during the quarter.
West Tower Group sold 31 United Therapeutics shares in Q1 2024, an estimated $6.82K.
West Tower Group first reported a position in United Therapeutics in Q4 2023 and held it in 1 quarter.
West Tower Group's United Therapeutics position peaked at $6.82K in Q4 2023.
525 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2024.

Based on West Tower Group's 13F filing for Q1 2024, filed 14 May 2024.